Indivior Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Oct 30, 2025, INDV reported earnings of 0.72 USD per share (EPS) for Q3 25, beating the estimate of 0.41 USD, resulting in a 71.47% surprise. Revenue reached 314.00 million, compared to an expected 267.16 million, with a 17.53% difference. The market reacted with a +15.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of 0.68 USD, with revenue projected to reach 311.73 million USD, implying an decrease of -5.56% EPS, and decrease of -0.72% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were Indivior Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Indivior Pharmaceuticals, Inc. Common Stock reported EPS of $0.72, beating estimates by 71.47%, and revenue of $314.00M, 17.53% above expectations.
How did the market react to Indivior Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 15.41%, changed from $25.24 before the earnings release to $29.13 the day after.
When is Indivior Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Indivior Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 7
analysts, Indivior Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.68 and revenue of $311.73M for Q4 2025.